Drug intelligence / Profile preview

Sanshimao formula

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

The Sanshimao (SSM) formula is a Traditional Chinese Medicine (TCM) herbal prescription specifically used for the treatment of hepatocellular carcinoma (HCC). It is a combination of four herbs: Maorenshen (Actinidia chinensis), Shijianchuan (Salvia chinensis), Shishangbai (Selaginella doederleinii), and Shidachuan (Salvia plebeia). Clinically, it is employed for its detoxification and blood-stasis-removing properties. Research indicates that the formula's therapeutic efficacy is linked to its ability to target the Epidermal Growth Factor Receptor (EGFR), thereby inhibiting the growth and progression of liver cancer cells. It is typically administered as an oral decoction.

Other names: SanshimaoSSMSSM formula

Targets

EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on Sanshimao formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sanshimao formula.

Explore the full profile